| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.14 | 0.002 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.5 | 0.003 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.006 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.16 | 0.007 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.16 | 0.007 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |